<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DAPTOMYCIN- daptomycin injection, powder, lyophilized, for solution </strong><br>Hospira, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DAPTOMYCIN FOR INJECTION safely and effectively. See full prescribing information for DAPTOMYCIN FOR INJECTION. <br>DAPTOMYCIN FOR INJECTION for Intravenous Use<br>Initial U.S. Approval: 2003<br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for Injection and other antibacterial drugs, Daptomycin for Injection should be used to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Warnings and Precautions (<a href="#ID_b5e3c9b9-8060-4cb2-9b80-25582b6961b7">5.5</a>)                                          1/2015 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: </p>
<dl>
<dt>•</dt>
<dd>Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI) (<a href="#f6988c9c-e780-4d8f-98c3-3fa458285840">1.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Staphylococcus aureus</span> bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>), including those with right-sided infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> (<a href="#de771702-8608-4df7-beb9-c3421803a892">1.2</a>)</dd>
</dl>
<p class="Highlighta">Daptomycin for Injection is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. (<a href="#a8c6422b-aa1a-4acb-819a-c22386f21df0">1.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Recommended dosage regimen for adult patients (<a href="#ffe15f61-e5a7-4775-a466-6c6195a345ad">2.2</a>, <a href="#ddb90923-d747-43e6-af7d-a24bbf319b6c">2.3</a>, <a href="#c473a928-a0be-4fdf-bfc8-138991d50649">2.4</a>):</dd>
</dl>
<table width="100%">
<col width="36%">
<col width="31%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Administered following hemodialysis on hemodialysis days.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="Highlighta"><span class="Emphasis"><span class="Bold">Creatinine Clearance (CL<span class="Sub">CR</span>)</span></span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="Highlighta"><span class="Emphasis"><span class="Bold">Dosage Regimen</span></span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="Highlighta"><span class="Emphasis"><span class="Bold"><span class="Underline">cSSSI<br></span>For 7 to 14 days</span></span> </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold"><span class="Underline"><span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span><br></span>For 2 to 6 weeks</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="Highlighta">≥30 mL/min </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="Highlighta">4 mg/kg<br>once every 24 hours </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="Highlighta">6 mg/kg<br>once every 24 hours </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="Highlighta">&lt;30 mL/min, including hemodialysis and CAPD </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="Highlighta">4 mg/kg </p>
<p class="Highlighta">once every 48 hours<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> </p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="Highlighta">6 mg/kg </p>
<p class="Highlighta">once every 48 hours<a href="#footnote-1" class="Sup">*</a> </p>
</td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>Administered intravenously in 0.9% sodium chloride, either by injection over a 2-minute period or by infusion over a 30-minute period. (<a href="#dc9d0802-5143-46eb-96b2-0370e904c8b7">2.1</a>, <a href="#f7cef314-a804-453f-b603-84601143a4b3">2.5</a>)</dd>
<dt>•</dt>
<dd>Do not use in conjunction with ReadyMED<span class="Sup">®</span> elastomeric infusion pumps. (<a href="#c1622b16-b7b1-46bb-9b4b-f5604a6de66c">2.7</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>500 mg lyophilized cake or powder for reconstitution in a single-use vial (<a href="#dee1acf1-d5e9-4c0b-89ff-bac79be920af">3</a>) </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to daptomycin (<a href="#be9d35f5-d74b-47fe-b1f8-8753d2301229">4</a>) </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including life-threatening): Discontinue Daptomycin for Injection and treat signs/symptoms. (<a href="#b17598ba-6b3c-4dc4-8dd0-263a3ca8d502">5.1</a>)     </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>: Monitor CPK levels and follow <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; if elevated CPK or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> occurs, consider discontinuation of Daptomycin for Injection. (<a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">5.2</a>)     </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">Eosinophilic pneumonia</span>: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (<a href="#dc1f3cc1-60ae-4db2-a0cd-cad307deb741">5.3</a>)     </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>: Monitor for <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> and consider discontinuation. (<a href="#a4a640d3-1841-4091-b207-fb44c213501f">5.4</a>)</dd>
<dt>•</dt>
<dd>Potential nervous system and/or muscular system effects in pediatric patients younger than 12 months: Avoid use of Daptomycin in this age group. (<a href="#ID_b5e3c9b9-8060-4cb2-9b80-25582b6961b7">5.5</a>)     </dd>
<dt>•</dt>
<dd>
<span class="Italics">Clostridium difficile</span>–associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: Evaluate patients if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#aa7bd111-c3f4-4a9f-9c6d-2d2b5c13ca4a">5.6</a>)     </dd>
<dt>•</dt>
<dd>Persisting or relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>: Perform susceptibility testing and rule out sequestered foci of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#cc0077c1-7e0a-4a79-9e34-7d3a46d0bf72">5.7</a>)     </dd>
<dt>•</dt>
<dd>Decreased efficacy was observed in patients with moderate baseline <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#c8cf2068-ffbc-457f-a970-46aae9371bea">5.8</a>)     </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most clinically significant adverse reactions observed with Daptomycin for Injection 4 mg/kg (cSSSI trials) and 6 mg/kg (<span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> trial) were <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, elevated CPK and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. (<a href="#e4da68d4-8043-4e40-8985-05840174049d">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="Italics">Staphylococcus aureus</span> Bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>), Including Those with Right-Sided Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Usage</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration Duration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="Italics">Staphylococcus aureus</span> Bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>), Including Those with Right-Sided Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Preparation of Daptomycin for Injection for Administration</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Compatible Intravenous Solutions</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Incompatibilities</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">Eosinophilic Pneumonia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5 Potential Nervous System and/or Muscular System Effects in Pediatric Patients Younger than 12 Months</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="Italics">Clostridium difficile</span>–Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Persisting or Relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Decreased Efficacy in Patients with Moderate Baseline <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Drug-Laboratory Test Interactions</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Non-Susceptible Microorganisms</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 HMG-CoA Reductase Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drug-Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="f12c0ba4-d452-49a6-b33f-280110f32fd1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Daptomycin for Injection is indicated for the treatment of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> listed below.</p>
<div class="Section" data-sectionCode="34067-9">
<a name="f6988c9c-e780-4d8f-98c3-3fa458285840"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: <span class="Italics">Staphylococcus aureus</span> (including methicillin-resistant isolates), <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus agalactiae</span>, <span class="Italics">Streptococcus dysgalactiae</span> subsp. <span class="Italics">equisimilis</span>, and <span class="Italics">Enterococcus faecalis</span> (vancomycin-susceptible isolates only).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="de771702-8608-4df7-beb9-c3421803a892"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="Italics">Staphylococcus aureus</span> Bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>), Including Those with Right-Sided Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates</h2>
<p class="First"><span class="Italics">Staphylococcus aureus</span> bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>), including those with right-sided infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, caused by methicillin-susceptible and methicillin-resistant isolates.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a8c6422b-aa1a-4acb-819a-c22386f21df0"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">Daptomycin for Injection is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p>Daptomycin for Injection is not indicated for the treatment of left-sided infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> due to <span class="Italics">S.</span><span class="Italics"> aureus</span>. The clinical trial of Daptomycin for Injection in patients with <span class="Italics">S. aureus</span> bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> included limited data from patients with left-sided infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>; outcomes in these patients were poor [<span class="Italics">see</span> <span class="Italics"><a href="#be967a28-5b0d-4f82-b7c2-1c36c2c748b5">Clinical Studies (14.2)</a></span>]. Daptomycin for Injection has not been studied in patients with prosthetic valve <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d16f397a-aaee-4a2f-a9b1-90fafc7ce0c4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Usage</h2>
<p class="First">Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for Injection and other antibacterial drugs, Daptomycin for Injection should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.</p>
<p>When culture and susceptibility information is available, it should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Empiric therapy may be initiated while awaiting test results.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d68e8b5e-3c2b-4b4f-bd88-5fa96b143afc"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="dc9d0802-5143-46eb-96b2-0370e904c8b7"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration Duration</h2>
<p class="First">Daptomycin for Injection should be administered intravenously either by injection over a two (2) minute period or by infusion over a thirty (30) minute period.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ffe15f61-e5a7-4775-a466-6c6195a345ad"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Daptomycin for Injection 4 mg/kg should be administered intravenously in 0.9% sodium chloride injection once every 24 hours for 7 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ddb90923-d747-43e6-af7d-a24bbf319b6c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="Italics">Staphylococcus aureus</span> Bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>), Including Those with Right-Sided Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates</h2>
<p class="First">Daptomycin for Injection 6 mg/kg should be administered intravenously in 0.9% sodium chloride injection once every 24 hours for 2 to 6 weeks. There are limited safety data for the use of Daptomycin for Injection for more than 28 days of therapy. In the Phase 3 trial, there were a total of 14 patients who were treated with Daptomycin for Injection for more than 28 days.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c473a928-a0be-4fdf-bfc8-138991d50649"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The recommended dosage regimen for patients with creatinine clearance (CL<span class="Sub">CR</span>) &lt;30 mL/min, including those on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), is 4 mg/kg (cSSSI) or 6 mg/kg (<span class="Italics">S. aureus</span> bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>) once every 48 hours (<a href="#_Ref419378663">Table 1</a>). When possible, Daptomycin for Injection should be administered following the completion of hemodialysis on hemodialysis days [<span class="Italics">see <a href="#f92e9a2d-1c00-45aa-998d-e0bd02231d61">Warnings and Precautions</a></span><span class="Emphasis"> </span><span class="Italics">(<a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">5.2</a><span class="Emphasis">, </span><a href="#c8cf2068-ffbc-457f-a970-46aae9371bea">5.8</a>), <a href="#d1175bfc-61e3-4d66-9947-e336a48b27e6">Use in Specific Populations (8.6)</a><span class="Emphasis">, </span>and</span> <span class="Italics"><a href="#c9bf3b09-a456-4c58-b2d3-fd1211e671e1">Clinical Pharmacology (12.3)</a></span>].</p>
<a name="_Ref419378663"></a><table width="100%">
<caption><span>Table 1. Recommended Dosage of Daptomycin for Injection in Adult Patients</span></caption>
<col width="31%">
<col width="35%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>When possible, administer Daptomycin for Injection following the completion of hemodialysis on hemodialysis days.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Creatinine Clearance (CL<span class="Sub">CR</span>)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Dosage Regimen</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">cSSSI</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Italics">S. aureus</span></span></p>
<p><span class="Bold">Bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">≥30 mL/min</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 mg/kg<br>once every 24 hours</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 mg/kg<br>once every 24 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">&lt;30 mL/min, including hemodialysis and CAPD</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 mg/kg<br>once every 48 hours<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 mg/kg <br>once every 48 hours<a href="#footnote-2" class="Sup">*</a></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f7cef314-a804-453f-b603-84601143a4b3"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Preparation of Daptomycin for Injection for Administration</h2>
<p class="First">Daptomycin for Injection is supplied in single-use vials, each containing 500 mg daptomycin as a sterile, lyophilized cake or powder. The contents of a Daptomycin for Injection vial should be reconstituted, using aseptic technique, to 50 mg/mL as follows:</p>
<p>Note: To minimize foaming, AVOID vigorous <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> of the vial during or after reconstitution.</p>
<dl>
<dt>1.</dt>
<dd>Remove the polypropylene flip-off cap from the Daptomycin for Injection vial to expose the central portion of the rubber stopper.</dd>
<dt>2.</dt>
<dd>Slowly transfer 10 mL of 0.9% sodium chloride injection through the center of the rubber stopper into the Daptomycin for Injection vial, pointing the transfer needle toward the wall of the vial.</dd>
<dt>3.</dt>
<dd>Ensure that all of the Daptomycin for Injection cake or powder is wetted by gently rotating the vial.</dd>
<dt>4.</dt>
<dd>Allow the wetted product to stand undisturbed for 10 minutes.</dd>
<dt>5.</dt>
<dd>Gently rotate or swirl the vial contents for a few minutes, as needed, to obtain a completely reconstituted solution.</dd>
</dl>
<p>For intravenous (IV) injection over a period of 2 minutes, administer the appropriate volume of the reconstituted Daptomycin for Injection (concentration of 50 mg/mL).</p>
<p>For IV infusion over a period of 30 minutes, the appropriate volume of the reconstituted Daptomycin for Injection (concentration of 50 mg/mL) should be further diluted, using aseptic technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride injection.</p>
<p>Parenteral drug products should be inspected visually for particulate matter prior to administration.</p>
<p>No preservative or bacteriostatic agent is present in this product. Aseptic technique must be used in the preparation of final IV solution. Stability studies have shown that the reconstituted solution is stable in the vial for 12 hours at room temperature and up to 48 hours if stored under refrigeration at 2 to 8°C (36 to 46°F).</p>
<p>The diluted solution is stable in the infusion bag for 12 hours at room temperature and 48 hours if stored under refrigeration. The combined storage time (reconstituted solution in vial and diluted solution in infusion bag) should not exceed 12 hours at room temperature or 48 hours under refrigeration.</p>
<p>Daptomycin for Injection vials are for single use only.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="fff47a29-458d-491f-b1a8-857f648e3b0e"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Compatible Intravenous Solutions</h2>
<p class="First">Daptomycin for Injection is compatible with 0.9% sodium chloride injection and lactated Ringer’s injection.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c1622b16-b7b1-46bb-9b4b-f5604a6de66c"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Incompatibilities</h2>
<p class="First">Daptomycin for Injection is not compatible with dextrose-containing diluents.</p>
<p>Daptomycin for Injection should not be used in conjunction with ReadyMED<span class="Sup">®</span> elastomeric infusion pumps (Cardinal Health, Inc.). Stability studies of Daptomycin for Injection solutions stored in ReadyMED<span class="Sup">®</span> elastomeric infusion pumps identified an impurity (2-mercaptobenzothiazole) leaching from this pump system into the Daptomycin for Injection solution.</p>
<p>Because only limited data are available on the compatibility of Daptomycin for Injection with other IV substances, additives and other medications should not be added to Daptomycin for Injection single-use vials or infusion bags, or infused simultaneously with Daptomycin for Injection through the same IV line. If the same IV line is used for sequential infusion of different drugs, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with a compatible intravenous solution before and after infusion with Daptomycin for Injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="dee1acf1-d5e9-4c0b-89ff-bac79be920af"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">500 mg daptomycin as a sterile, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light brown lyophilized cake or powder for reconstitution in a single-use vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="be9d35f5-d74b-47fe-b1f8-8753d2301229"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Daptomycin for Injection is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to daptomycin.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f92e9a2d-1c00-45aa-998d-e0bd02231d61"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="b17598ba-6b3c-4dc4-8dd0-263a3ca8d502"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported with the use of antibacterial agents, including Daptomycin for Injection, and may be life-threatening. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Daptomycin for Injection occurs, discontinue the drug and institute appropriate therapy [<span class="Italics">see</span> <span class="Italics"><a href="#b1bd7095-d5fd-4a17-be0e-6ccb36459e69">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f98a3b2e-65f7-49b0-8af8-63be628e4e15"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>, defined as muscle aching or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), has been reported with the use of Daptomycin for Injection. <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>, with or without <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, has been reported [<span class="Italics">see</span> <span class="Italics"><a href="#b1bd7095-d5fd-4a17-be0e-6ccb36459e69">Adverse Reactions (6.2)</a></span>].</p>
<p>Patients receiving Daptomycin for Injection should be monitored for the development of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly of the distal extremities. In patients who receive Daptomycin for Injection, CPK levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur during treatment with Daptomycin for Injection.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, both renal function and CPK should be monitored more frequently than once weekly [<span class="Italics">see</span> <span class="Italics"><a href="#d1175bfc-61e3-4d66-9947-e336a48b27e6">Use in Specific Populations (8.6)</a></span> <span class="Italics">and</span> <span class="Italics"><a href="#c9bf3b09-a456-4c58-b2d3-fd1211e671e1">Clinical Pharmacology (12.3)</a></span>].</p>
<p>In Phase 1 studies and Phase 2 clinical trials, CPK elevations appeared to be more frequent when Daptomycin for Injection was dosed more than once daily. Therefore, Daptomycin for Injection should not be dosed more frequently than once a day.</p>
<p>Daptomycin for Injection should be discontinued in patients with unexplained signs and symptoms of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in conjunction with CPK elevations to levels &gt;1,000 U/L (~5× ULN), and in patients without reported symptoms who have marked elevations in CPK, with levels &gt;2,000 U/L (≥10× ULN). In addition, consideration should be given to suspending agents associated with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, such as HMG-CoA reductase inhibitors, temporarily in patients receiving Daptomycin for Injection [<span class="Italics">see</span> <span class="Italics"><a href="#b2f3d3a1-4a3b-413f-a83d-0ec28c48e410">Drug Interactions (7.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="dc1f3cc1-60ae-4db2-a0cd-cad307deb741"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">Eosinophilic Pneumonia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">Eosinophilic pneumonia</span> has been reported in patients receiving Daptomycin for Injection [<span class="Italics">see</span> <span class="Italics"><a href="#b1bd7095-d5fd-4a17-be0e-6ccb36459e69">Adverse Reactions (6.2)</a></span>]. In reported cases associated with Daptomycin for Injection, patients developed <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxic</span> <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, and diffuse pulmonary infiltrates. In general, patients developed <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span> 2 to 4 weeks after starting Daptomycin for Injection and improved when Daptomycin for Injection was discontinued and steroid therapy was initiated. Recurrence of <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span> upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving Daptomycin for Injection should undergo prompt medical evaluation, and Daptomycin for Injection should be discontinued immediately. Treatment with systemic steroids is recommended.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="a4a640d3-1841-4091-b207-fb44c213501f"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> have been reported during the Daptomycin for Injection postmarketing experience [<span class="Italics">see</span> <span class="Italics"><a href="#b1bd7095-d5fd-4a17-be0e-6ccb36459e69">Adverse Reactions (6.2)</a></span>]. Therefore, physicians should be alert to signs and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> in patients receiving Daptomycin for Injection.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_b5e3c9b9-8060-4cb2-9b80-25582b6961b7"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5 Potential Nervous System and/or Muscular System Effects in Pediatric Patients Younger than 12 Months</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Avoid use of Daptomycin for Injection in pediatric patients younger than 12 months due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs with intravenous daptomycin [<span class="Italics">see <a href="#da55a8b1-24bc-4507-b2d6-120464381270">Nonclinical Toxicology (13.2)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="aa7bd111-c3f4-4a9f-9c6d-2d2b5c13ca4a"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="Italics">Clostridium difficile</span>–Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span>–associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with the use of nearly all systemic antibacterial agents, including Daptomycin for Injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> [<span class="Italics">see <a href="#b1bd7095-d5fd-4a17-be0e-6ccb36459e69">Adverse Reactions (6.2)</a></span>]. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, since these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="cc0077c1-7e0a-4a79-9e34-7d3a46d0bf72"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Persisting or Relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></h2>
<p class="First">Patients with persisting or relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> or poor clinical response should have repeat blood cultures. If a blood culture is positive for <span class="Italics">S. aureus</span>, <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) susceptibility testing of the isolate should be performed using a standardized procedure, and diagnostic evaluation of the patient should be performed to rule out sequestered foci of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Appropriate <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> (e.g., debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial regimen may be required.</p>
<p>Failure of treatment due to persisting or relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> may be due to reduced daptomycin susceptibility (as evidenced by increasing MIC of the <span class="Italics">S. aureus</span> isolate) [<span class="Italics">see</span> <span class="Italics"><a href="#be967a28-5b0d-4f82-b7c2-1c36c2c748b5">Clinical Studies (14.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="c8cf2068-ffbc-457f-a970-46aae9371bea"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Decreased Efficacy in Patients with Moderate Baseline <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Limited data are available from the two Phase 3 complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (cSSSI) clinical trials regarding clinical efficacy of daptomycin treatment in patients with creatinine clearance (CL<span class="Sub">CR</span>) &lt;50 mL/min; only 31/534 (6%) patients treated with daptomycin in the intent-to-treat (ITT) population had a baseline CL<span class="Sub">CR</span> &lt;50 mL/min. <a href="#_Ref419380404">Table 2</a> shows the number of patients by renal function and treatment group who were clinical successes in the Phase 3 cSSSI trials.</p>
<a name="_Ref419380404"></a><table width="100%">
<caption><span>Table 2. Clinical Success Rates by Renal Function and Treatment Group in Phase 3 cSSSI Trials (Population: ITT)</span></caption>
<col width="32%">
<col width="34%">
<col width="34%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">CL<span class="Sub">CR</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Success Rate</span></span><br><span class="Emphasis"><span class="Bold">n/N (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Daptomycin</span></span><br><span class="Emphasis"><span class="Bold">4 mg/kg q24h</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Comparator</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">50-70 mL/min</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25/38 (66%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30/48 (63%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">30-&lt;50 mL/min </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7/15 (47%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">20/35 (57%)</p></td>
</tr>
</tbody>
</table>
<p>In a subgroup analysis of the ITT population in the Phase 3 <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> trial, clinical success rates, as determined by a treatment-blinded Adjudication Committee [<span class="Italics">see</span><span class="Emphasis"> </span><span class="Italics"><a href="#be967a28-5b0d-4f82-b7c2-1c36c2c748b5">Clinical Studies (14.2)</a></span>], in the daptomycin-treated patients were lower in patients with baseline CL<span class="Sub">CR</span> &lt;50 mL/min (see <a href="#_Ref419380580">Table 3</a>). A decrease of the magnitude shown in <a href="#_Ref419380580">Table 3</a> was not observed in comparator-treated patients. </p>
<a name="_Ref419380580"></a><table width="100%">
<caption><span>Table 3. Adjudication Committee Clinical Success Rates at Test of Cure by Baseline Creatinine Clearance and Treatment Subgroup in the S. aureus <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> Trial (Population: ITT)</span></caption>
<col width="23%">
<col width="21%">
<col width="20%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Baseline CL<span class="Sub">CR</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle"><p class="First"><span class="Emphasis"><span class="Bold">Success Rate</span></span><br><span class="Emphasis"><span class="Bold">n/N (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Daptomycin 6 mg/kg q24h</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Comparator</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Right-Sided</span></span><br><span class="Emphasis"><span class="Bold">Infective</span></span><br><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Right-Sided</span></span><br><span class="Emphasis"><span class="Bold">Infective</span></span><br><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">&gt;80 mL/min</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30/50 (60%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7/14 (50%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19/42 (45%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5/11 (46%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">50-80 mL/min</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12/26 (46%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1/4 (25%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13/31 (42%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1/2 (50%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">30-&lt;50 mL/min</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2/14 (14%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0/1 (0%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7/17 (41%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1/1 (100%)</p></td>
</tr>
</tbody>
</table>
<p>Consider these data when selecting antibacterial therapy for use in patients with baseline moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="c35c6bc0-cc18-4f0d-9be3-29368becfff5"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Drug-Laboratory Test Interactions</h2>
<p class="First">Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay [<span class="Italics">see</span> <span class="Italics"><a href="#dd31d0ff-4d12-4fae-b397-33f9616fab72">Drug Interactions (7.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="d4fe3ff5-b740-4071-a7c7-e4ae8ef61bd3"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Non-Susceptible Microorganisms</h2>
<p class="First">The use of antibacterials may promote the overgrowth of non-susceptible microorganisms. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Prescribing Daptomycin for Injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="cfc57ee5-75f3-4f81-918e-894d3c2c6a9d"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described, or described in greater detail, in other sections:</p>
<dl>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> [<span class="Italics">see</span> <span class="Italics"><a href="#b17598ba-6b3c-4dc4-8dd0-263a3ca8d502">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> [<span class="Italics">see</span> <span class="Italics"><a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">Warnings and Precautions (5.2)</a></span>]</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">Eosinophilic pneumonia</span> [<span class="Italics">see</span> <span class="Italics"><a href="#dc1f3cc1-60ae-4db2-a0cd-cad307deb741">Warnings and Precautions (5.3)</a></span>]</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> [<span class="Italics">see</span> <span class="Italics"><a href="#a4a640d3-1841-4091-b207-fb44c213501f">Warnings and Precautions (5.4)</a></span>]</dd>
<dt>-</dt>
<dd>Increased International Normalized Ratio (INR)/prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time [<span class="Italics">see</span> <span class="Italics"><a href="#c35c6bc0-cc18-4f0d-9be3-29368becfff5">Warnings and Precautions (5.9)</a></span> <span class="Italics">and</span> <span class="Italics"><a href="#dd31d0ff-4d12-4fae-b397-33f9616fab72">Drug Interactions (7.2)</a></span>]</dd>
</dl>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="e4da68d4-8043-4e40-8985-05840174049d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Clinical trials enrolled 1,864 patients treated with Daptomycin for Injection and 1,416 treated with comparator.</p>
<p><span class="Emphasis"><span class="Bold">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Trials</span></span></p>
<p>In Phase 3 complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (cSSSI) trials, Daptomycin for Injection was discontinued in 15/534 (2.8%) patients due to an adverse reaction, while comparator was discontinued in 17/558 (3.0%) patients.</p>
<p>The rates of the most common adverse reactions, organized by body system, observed in cSSSI (4 mg/kg Daptomycin for Injection) patients are displayed in <a href="#_Ref419381185">Table 4</a>.</p>
<a name="_Ref419381185"></a><table width="100%">
<caption><span>Table 4. Incidence of Adverse Reactions that Occurred in ≥2% of Patients in the Daptomycin for Injection Treatment Group and ≥ the Comparator Treatment Groups in Phase 3 cSSSI Trials</span></caption>
<col width="34%">
<col width="34%">
<col width="32%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Adverse Reaction</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Emphasis"><span class="Bold">Patients (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Daptomycin for Injection</span></span><br><span class="Emphasis"><span class="Bold">4 mg/kg (N=534)</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Comparator</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span><br><span class="Emphasis"><span class="Bold">(N=558)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></span><br>    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">4.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></span><br>    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">5.4<br>2.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">5.4<br>2.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold">Skin/subcutaneous disorders</span></span><br>    <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">4.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">3.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold">Diagnostic investigations</span></span><br>    <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Abnormal liver function tests</span><br>    Elevated CPK</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">3.0<br>2.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1.6<br>1.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span><br>    <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></span><br>    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span></span></span><br>    <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1.6</p></td>
</tr>
</tbody>
</table>
<p>Drug-related adverse reactions (possibly or probably drug-related) that occurred in &lt;1% of patients receiving Daptomycin for Injection in the cSSSI trials are as follows:</p>
<p><span class="Italics">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span><br><span class="Italics">Blood/Lymphatic System</span>: <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, increased International Normalized Ratio (INR)<br><span class="Italics">Cardiovascular System</span>: supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span><br><span class="Italics">Dermatologic System</span>: <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span><br><span class="Italics">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, increased <span class="product-label-link" type="condition" conceptid="4121879" conceptname="Lactate dehydrogenase">serum lactate dehydrogenase</span><br><span class="Italics">Metabolic/Nutritional System</span>: <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, increased serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbance</span><br><span class="Italics">Musculoskeletal System</span>: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span><br><span class="Italics">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, mental status change, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span><br><span class="Italics">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span></p>
<p><span class="Bold"><span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> Trial</span></p>
<p>In the <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> trial, Daptomycin for Injection was discontinued in 20/120 (16.7%) patients due to an adverse reaction, while comparator was discontinued in 21/116 (18.1%) patients.</p>
<p>Serious Gram-negative <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (including bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>) were reported in 10/120 (8.3%) Daptomycin for Injection-treated and 0/115 comparator-treated patients. Comparator-treated patients received dual therapy that included initial gentamicin for 4 days. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> were reported during treatment and during early and late follow-up. Gram-negative <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> included <span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">cholangitis</span>, <span class="product-label-link" type="condition" conceptid="40483827" conceptname="Alcohol-induced pancreatitis">alcoholic pancreatitis</span>, sternal <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>/<span class="product-label-link" type="condition" conceptid="439045" conceptname="Mediastinitis">mediastinitis</span>, bowel <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, recurrent Crohn’s disease, recurrent line <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, and recurrent <span class="product-label-link" type="condition" conceptid="4159744" conceptname="Urosepsis">urosepsis</span> caused by a number of different Gram-negative bacteria.</p>
<p>The rates of the most common adverse reactions, organized by System Organ Class (SOC), observed in <span class="Italics">S.</span><span class="Italics"> aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> (6 mg/kg Daptomycin for Injection) patients are displayed in <a href="#_Ref419442430">Table 5</a>.</p>
<a name="_Ref419442430"></a><table width="100%">
<caption><span>Table 5. Incidence of Adverse Reactions that Occurred in ≥5% of Patients in the Daptomycin for Injection Treatment Group and ≥ to the Comparator Treatment Group in the S. aureus <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> Trial</span></caption>
<col width="57%">
<col width="22%">
<col width="21%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>NOS, not otherwise specified.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV q4h), each with initial low-dose gentamicin.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Adverse Reaction</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Emphasis"><span class="Bold">Patients</span></span><br><span class="Emphasis"><span class="Bold">n (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Daptomycin</span></span><br><span class="Emphasis"><span class="Bold">for Injection</span></span><br><span class="Emphasis"><span class="Bold">6 mg/kg</span></span><br><span class="Emphasis"><span class="Bold">(N=120)</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Comparator</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a><span class="Emphasis"> </span></span><br><span class="Emphasis"><span class="Bold">(N=116)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></span></p>
<p>    <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> NOS<br>    <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">6 (5%)</p>
<p>6 (5%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">3 (3%)</p>
<p>0 (0%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></span></p>
<p>    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> NOS</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">7 (6%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">4 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold">General disorders and administration site conditions</span></span></p>
<p>    <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span><br>    <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> NOS</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">8 (7%)</p>
<p>8 (7%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">7 (6%)</p>
<p>5 (4%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></span></p>
<p>    Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">10 (8%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold">Skin and subcutaneous tissue disorders</span></span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span><br>    <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating increased</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">7 (6%)</p>
<p>6 (5%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">6 (5%)</p>
<p>0 (0%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold">Psychiatric disorders</span></span></p>
<p>    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">11 (9%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">8 (7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold">Investigations</span></span><br>    <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">Blood creatine phosphokinase</span> increased</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">8 (7%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1 (1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></span></p>
<p>    <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> NOS </p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">7 (6%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">3 (3%)</p></td>
</tr>
</tbody>
</table>
<p>The following reactions, not included above, were reported as possibly or probably drug-related in the Daptomycin for Injection-treated group:</p>
<p><span class="Italics">Blood and Lymphatic System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span><br><span class="Italics">Ear and Labyrinth Disorders</span>: <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>, <span class="product-label-link" type="condition" conceptid="4009488" conceptname="Sore gums">gingival pain</span>, <span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">hypoesthesia oral</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidal infection</span> NOS, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4202922" conceptname="Fungemia">fungemia</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> fungal<br><span class="Italics">Investigations</span>: blood phosphorous increased, blood alkaline phosphatase increased, INR increased, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin time prolonged</span><br><span class="Italics">Metabolism and Nutrition Disorders</span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span> NOS<br><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span><br><span class="Italics">Psychiatric Disorders</span>: <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span> NOS<br><span class="Italics">Renal and Urinary Disorders</span>: <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> NOS<br><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">pruritus generalized</span>, <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span></p>
<p><span class="Bold">Other Trials</span></p>
<p>In Phase 3 trials of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (CAP), the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> rate and rates of serious cardiorespiratory adverse events were higher in Daptomycin for Injection-treated patients than in comparator-treated patients. These differences were due to lack of therapeutic effectiveness of Daptomycin for Injection in the treatment of CAP in patients experiencing these adverse events [<span class="Italics">see</span> <span class="Italics"><a href="#a8c6422b-aa1a-4acb-819a-c22386f21df0">Indications and Usage (1.3)</a></span>].</p>
<p><span class="Emphasis"><span class="Bold">Laboratory Changes</span></span></p>
<p><span class="Emphasis"><span class="Bold">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Trials</span></span></p>
<p>In Phase 3 cSSSI trials of Daptomycin for Injection at a dose of 4 mg/kg, elevations in CPK were reported as clinical adverse events in 15/534 (2.8%) Daptomycin for Injection-treated patients, compared with 10/558 (1.8%) comparator-treated patients. Of the 534 patients treated with Daptomycin for Injection, 1 (0.2%) had symptoms of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> associated with CPK elevations to greater than 4 times the upper limit of normal (ULN). The symptoms resolved within 3 days and CPK returned to normal within 7 to 10 days after treatment was discontinued [<span class="Italics">see</span> <span class="Italics"><a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">Warnings and Precautions (5.2)</a></span>]. <a href="#_Ref419442872">Table 6</a> summarizes the CPK shifts from Baseline through End of Therapy in the cSSSI trials. </p>
<a name="_Ref419442872"></a><table width="100%">
<caption><span>Table 6. Incidence of CPK Elevations from Baseline during Therapy in Either the Daptomycin for Injection Treatment Group or the Comparator Treatment Group in Phase 3 cSSSI Trials</span></caption>
<col width="23%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="9%">
<col width="11%">
<col width="8%">
<col width="11%">
<col width="8%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="15" valign="top">Note: Elevations in CPK observed in patients treated with Daptomycin for Injection or comparator were not clinically or statistically significantly different.</td></tr>
<tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>ULN (Upper Limit of Normal) is defined as 200 U/L.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="bottom"><p class="First"><span class="Bold">Change in CPK</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="bottom"><p class="First"><span class="Bold">All Patients</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top">
<p class="First"><span class="Bold">Patients with Normal CPK</span></p>
<p><span class="Bold">at Baseline</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Daptomycin for</span></p>
<p><span class="Bold">Injection</span></p>
<p><span class="Bold">4 mg/kg</span></p>
<p><span class="Bold">(N=430)</span></p>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Comparator<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></p>
<p><span class="Bold">(N=459)</span></p>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Daptomycin for</span></p>
<p><span class="Bold">Injection</span></p>
<p><span class="Bold">4 mg/kg</span></p>
<p><span class="Bold">(N=374)</span></p>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Comparator<a href="#footnote-6" class="Sup">*</a></span></p>
<p><span class="Bold">(N=392)</span></p>
</td>
</tr>
<tr>
<td align="center" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No Increase</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">90.7</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">390</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">91.1</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">418</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">91.2</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">341</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">91.1</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">357</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Maximum</p>
<p>Value &gt;1× ULN<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p>
</td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First">9.3</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">40</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First">8.9</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">41</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First">8.8</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">33</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First">8.9</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">35</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">           &gt;2× ULN</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">4.9</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">4.8</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">3.7</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">3.1</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">           &gt;4× ULN</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">           &gt;5× ULN</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">           &gt;10× ULN</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">S. aureus</span></span> <span class="Bold"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> Trial</span></p>
<p>In the <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> trial, at a dose of 6 mg/kg, 11/120 (9.2%) Daptomycin for Injection-treated patients, including two patients with baseline CPK levels &gt;500 U/L, had CPK elevations to levels &gt;500 U/L, compared with 1/116 (0.9%) comparator-treated patients. Of the 11 Daptomycin for Injection-treated patients, 4 had prior or concomitant treatment with an HMG-CoA reductase inhibitor. Three of these 11 Daptomycin for Injection-treated patients discontinued therapy due to CPK elevation, while the one comparator-treated patient did not discontinue therapy [<span class="Italics">see</span> <span class="Italics"><a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b1bd7095-d5fd-4a17-be0e-6ccb36459e69"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Daptomycin for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, difficulty swallowing, truncal <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="252942" conceptname="Asthmatic pulmonary eosinophilia">pulmonary eosinophilia</span> [<span class="Italics">see</span> <span class="Italics"><a href="#be9d35f5-d74b-47fe-b1f8-8753d2301229">Contraindications (4)</a><span class="Emphasis">,</span></span><span class="Emphasis"> </span><span class="Italics"><a href="#b17598ba-6b3c-4dc4-8dd0-263a3ca8d502">Warnings and Precautions (5.1)</a></span>]<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="Italics">Clostridium difficile</span>–associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [<span class="Italics">see</span> <span class="Italics"><a href="#aa7bd111-c3f4-4a9f-9c6d-2d2b5c13ca4a">Warnings and Precautions (5.6)</a></span>]<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span></span>: myoglobin increased; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (some reports involved patients treated concurrently with Daptomycin for Injection and HMG-CoA reductase inhibitors) [<span class="Italics">see</span> <span class="Italics"><a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">Warnings and Precautions (5.2)</a></span><span class="Italics">, </span><span class="Italics"><a href="#b2f3d3a1-4a3b-413f-a83d-0ec28c48e410">Drug Interactions (7.1)</a>,</span> <span class="Italics">and</span> <span class="Italics"><a href="#c9bf3b09-a456-4c58-b2d3-fd1211e671e1">Clinical Pharmacology (12.3)</a></span>]<br><span class="Italics">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span> [<span class="Italics">see</span><span class="Emphasis"> </span><span class="Italics"><a href="#dc1f3cc1-60ae-4db2-a0cd-cad307deb741">Warnings and Precautions (5.3)</a></span>]<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> [<span class="Italics">see</span> <span class="Italics"><a href="#a4a640d3-1841-4091-b207-fb44c213501f">Warnings and Precautions (5.4)</a></span>]<br><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>: serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span> (with or without mucous membrane involvement)<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="e4f54bc9-a55b-4a10-8703-cb6e508695db"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="b2f3d3a1-4a3b-413f-a83d-0ec28c48e410"></a><a name="section-7.1"></a><p></p>
<h2>7.1 HMG-CoA Reductase Inhibitors</h2>
<p class="First">In healthy subjects, concomitant administration of Daptomycin for Injection and simvastatin had no effect on plasma trough concentrations of simvastatin, and there were no reports of skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> [<span class="Italics">see</span> <span class="Italics"><a href="#c9bf3b09-a456-4c58-b2d3-fd1211e671e1">Clinical Pharmacology (12.3)</a></span>].</p>
<p>However, inhibitors of HMG-CoA reductase may cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, which is manifested as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> associated with elevated levels of creatine phosphokinase (CPK). In the Phase 3 <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> trial, some patients who received prior or concomitant treatment with an HMG-CoA reductase inhibitor developed elevated CPK [<span class="Italics">see</span> <span class="Italics"><a href="#e4da68d4-8043-4e40-8985-05840174049d">Adverse Reactions (6.1)</a></span>]. Experience with the coadministration of HMG-CoA reductase inhibitors and Daptomycin for Injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin for Injection.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="dd31d0ff-4d12-4fae-b397-33f9616fab72"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drug-Laboratory Test Interactions</h2>
<p class="First">Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay. The possibility of an erroneously elevated PT/INR result due to interaction with a recombinant thromboplastin reagent may be minimized by drawing specimens for PT or INR testing near the time of trough plasma concentrations of daptomycin. However, sufficient daptomycin concentrations may be present at trough to cause interaction.</p>
<p>If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin for Injection, it is recommended that clinicians:</p>
<dl>
<dt>1.</dt>
<dd>Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin for Injection dose (i.e., at trough concentration). If the PT/INR value obtained at trough remains substantially elevated above what would otherwise be expected, consider evaluating PT/INR utilizing an alternative method. </dd>
<dt>2.</dt>
<dd>Evaluate for other causes of abnormally elevated PT/INR results. </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="a12e872f-82b3-4d8a-94ee-64932495052d"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="c701603b-965d-414d-98a4-8809731c0c3c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Emphasis"><span class="Bold">Teratogenic Effects: Pregnancy Category B</span></span></p>
<p>There are no adequate and well-controlled trials of Daptomycin for Injection in pregnant women. Embryofetal development studies performed in rats and rabbits at doses of up to 75 mg/kg (2 and 4 times the 6 mg/kg human dose, respectively, on a body surface area basis) revealed no evidence of harm to the fetus due to daptomycin. Because animal reproduction studies are not always predictive of human response, Daptomycin for Injection should be used during pregnancy only if the potential benefit outweighs the possible risk. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="e5802f31-39e4-47a5-8682-1e8f5dba4756"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Daptomycin is present in human milk but is poorly bioavailable orally. In a single case study, daptomycin was administered daily for 28 days to a nursing mother at an IV dose of 6.7 mg/kg/day, and samples of the patient’s breast milk were collected over a 24-hour period on day 27. The highest measured concentration of daptomycin in the breast milk was 0.045 mcg/mL<span class="Sup">1</span>. The calculated maximum daily daptomycin dose to the infant (assuming mean milk consumption of 150 mL/kg/day) was 0.1% of the maternal dose (6.7 mg/kg/day). Caution should be exercised when daptomycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ea669be4-d719-433a-b23e-c3adddee685c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of Daptomycin for Injection in pediatric patients have not been established. Avoid use of Daptomycin for Injection in pediatric patients younger than 12 months due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs [<span class="Italics">see<span class="Emphasis"> </span><a href="#ID_b5e3c9b9-8060-4cb2-9b80-25582b6961b7">Warnings and Precautions (5.5)</a><span class="Emphasis"> and </span><a href="#da55a8b1-24bc-4507-b2d6-120464381270">Nonclinical Toxicology (13.2)</a></span>]<span class="Emphasis">.</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="a95cb527-871d-4be4-a666-b2828517e026"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 534 patients treated with Daptomycin for Injection in Phase 3 controlled clinical trials of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI), 27% were 65 years of age or older and 12% were 75 years of age or older. Of the 120 patients treated with Daptomycin for Injection in the Phase 3 controlled clinical trial of <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, 25% were 65 years of age or older and 16% were 75 years of age or older. In Phase 3 clinical trials of cSSSI and <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, clinical success rates were lower in patients ≥65 years of age than in patients &lt;65 years of age. In addition, treatment-emergent adverse events were more common in patients ≥65 years of age than in patients &lt;65 years of age.</p>
<p>The exposure of daptomycin was higher in healthy elderly subjects than in healthy young subjects. However, no adjustment of Daptomycin for Injection dosage is warranted for elderly patients with creatinine clearance (CL<span class="Sub">CR</span>) ≥30 mL/min [<span class="Italics">see</span> <span class="Italics"><a href="#c473a928-a0be-4fdf-bfc8-138991d50649">Dosage and Administration (2.4)</a></span> <span class="Italics">and</span> <span class="Italics"><a href="#c9bf3b09-a456-4c58-b2d3-fd1211e671e1">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="d1175bfc-61e3-4d66-9947-e336a48b27e6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Daptomycin is eliminated primarily by the kidneys; therefore, a modification of Daptomycin for Injection dosage interval is recommended for patients with CL<span class="Sub">CR</span> &lt;30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, both renal function and creatine phosphokinase (CPK) should be monitored more frequently than once weekly [<span class="Italics">see</span> <span class="Italics"><a href="#c473a928-a0be-4fdf-bfc8-138991d50649">Dosage and Administration (2.4)</a></span>, <span class="Italics"><a href="#f92e9a2d-1c00-45aa-998d-e0bd02231d61">Warnings and Precautions</a></span><span class="Emphasis"> </span><span class="Italics">(<a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">5.2</a></span><span class="Emphasis">, </span><span class="Italics"><a href="#c8cf2068-ffbc-457f-a970-46aae9371bea">5.8</a>)</span>, <span class="Italics">and</span> <span class="Italics"><a href="#c9bf3b09-a456-4c58-b2d3-fd1211e671e1">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="c87d87e1-620d-4d82-b61e-e6adf3942195"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In the event of overdosage, supportive care is advised with maintenance of glomerular filtration. Daptomycin is cleared slowly from the body by hemodialysis (approximately 15% of the administered dose is removed over 4 hours) and by peritoneal dialysis (approximately 11% of the administered dose is removed over 48 hours). The use of high-flux dialysis membranes during 4 hours of hemodialysis may increase the percentage of dose removed compared with that removed by low-flux membranes.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="b4874cc7-bccf-4238-af7c-5771eb25871f"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Daptomycin for Injection contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of <span class="Italics">Streptomyces roseosporus</span>. The chemical name is <span class="Italics">N</span>-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-<span class="Italics">threo</span>-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine ε<span class="Sub">1</span>-lactone. The chemical structure is:</p>
<div class="Figure">
<a name="id-97337049"></a><img alt="structural formula daptomycin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e33053a5-38cd-4a34-8566-208f94f55714&amp;name=daptomycin-for-injection1-figure-1-GDaptomycin.jpg">
</div>
<p>The empirical formula is C<span class="Sub">72</span>H<span class="Sub">101</span>N<span class="Sub">17</span>O<span class="Sub">26</span>; the molecular weight is 1620.67. Daptomycin for Injection is supplied in a single-use vial as a sterile, preservative-free, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light brown, lyophilized cake or powder containing approximately 500 mg of daptomycin for intravenous (IV) use following reconstitution with 0.9% sodium chloride injection [<span class="Italics">see</span><span class="Emphasis"> </span><span class="Italics"><a href="#f7cef314-a804-453f-b603-84601143a4b3">Dosage and Administration (2.5)</a></span>]. The only inactive ingredient is sodium hydroxide, which is used in minimal quantities for pH adjustment. Freshly reconstituted solutions of Daptomycin for Injection range in color from <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light brown.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f6327676-777e-40bb-a0dc-489772a58014"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="a67d79e5-c20a-4c63-8873-7aca668ffebb"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Daptomycin is an antibacterial drug [<span class="Italics">see</span> <span class="Italics"><a href="#bf76f40d-2184-461c-bf01-77aadbbd3897">Clinical Pharmacology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ebfd807c-d630-477c-a724-090623b8017b"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Based on animal models of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>) ratio for certain pathogens, including <span class="Italics">S. aureus</span>. The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with Daptomycin for Injection.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="c9bf3b09-a456-4c58-b2d3-fd1211e671e1"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Emphasis"><span class="Bold">Daptomycin for Injection Administered over a 30-Minute Period</span></span></p>
<p>The mean and standard deviation (SD) pharmacokinetic parameters of daptomycin at steady-state following intravenous (IV) administration of Daptomycin for Injection over a 30-minute period at 4 to 12 mg/kg q24h to healthy young adults are summarized in <a href="#_Ref419444354">Table 7</a>.</p>
<a name="_Ref419444354"></a><table width="100%">
<caption><span>Table 7. Mean (SD) Daptomycin Pharmacokinetic Parameters in Healthy Volunteers at Steady-State</span></caption>
<col width="17%">
<col width="19%">
<col width="16%">
<col width="18%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Daptomycin for Injection was administered by IV infusion over a 30-minute period.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Doses of Daptomycin for Injection in excess of 6 mg/kg have not been approved.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>AUC<span class="Sub">0-24</span>, area under the concentration-time curve from 0 to 24 hours; t<span class="Sub">1/2</span>, elimination half-life; V<span class="Sub">ss</span>, volume of distribution at steady-state; CL<span class="Sub">T</span>, total plasma clearance; C<span class="Sub">max</span>, maximum plasma concentration.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Dose</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a></span></p>
<p><span class="Emphasis"><span class="Bold">(mg/kg)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Pharmacokinetic Parameters</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">AUC<span class="Sub">0-24</span></span></span></p>
<p><span class="Emphasis"><span class="Bold">(mcg•h/mL)</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">t<span class="Sub">1/2</span></span></span></p>
<p><span class="Emphasis"><span class="Bold">(h)</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">V<span class="Sub">ss</span></span></span></p>
<p><span class="Emphasis"><span class="Bold">(L/kg)</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">CL<span class="Sub">T</span></span></span></p>
<p><span class="Emphasis"><span class="Bold">(mL/h/kg)</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">C<span class="Sub">max</span></span></span></p>
<p><span class="Emphasis"><span class="Bold">(mcg/mL)</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 (N=6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">494 (75)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.1 (1.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.096 (0.009)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.3 (1.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">57.8 (3.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 (N=6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">632 (78)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.9 (1.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.101 (0.007)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.1 (1.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">93.9 (6.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8 (N=6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">858 (213)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.3 (2.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.101 (0.013)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.0 (3.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">123.3 (16.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 (N=9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1039 (178)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.9 (0.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.098 (0.017)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8 (2.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">141.1 (24.0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12 (N=9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1277 (253)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.7 (1.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.097 (0.018)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.0 (2.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">183.7 (25.0)</p></td>
</tr>
</tbody>
</table>
<p>Daptomycin pharmacokinetics were generally linear and time-independent at Daptomycin for Injection doses of 4 to 12 mg/kg q24h administered by IV infusion over a 30-minute period for up to 14 days. Steady-state trough concentrations were achieved by the third daily dose. The mean (SD) steady-state trough concentrations attained following the administration of 4, 6, 8, 10, and 12 mg/kg q24h were 5.9 (1.6), 6.7 (1.6), 10.3 (5.5), 12.9 (2.9), and 13.7 (5.2) mcg/mL, respectively.</p>
<p><span class="Emphasis"><span class="Bold">Daptomycin for Injection Administered over a 2-Minute Period</span></span></p>
<p>Following IV administration of Daptomycin for Injection over a 2-minute period to healthy volunteers at doses of 4 mg/kg (N=8) and 6 mg/kg (N=12), the mean (SD) steady-state systemic exposure (AUC) values were 475 (71) and 701 (82) mcg•h/mL, respectively. Values for maximum plasma concentration (C<span class="Sub">max</span>) at the end of the 2-minute period could not be determined adequately in this study. However, using pharmacokinetic parameters from 14 healthy volunteers who received a single dose of Daptomycin for Injection 6 mg/kg IV administered over a 30-minute period in a separate study, steady-state C<span class="Sub">max</span> values were simulated for Daptomycin for Injection 4 and 6 mg/kg IV administered over a 2-minute period. The simulated mean (SD) steady-state C<span class="Sub">max</span> values were 77.7 (8.1) and 116.6 (12.2) mcg/mL, respectively.</p>
<p><span class="Emphasis"><span class="Bold">Distribution</span></span></p>
<p>Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranges from 90 to 93%.</p>
<p>In clinical studies, mean serum protein binding in subjects with creatinine clearance (CL<span class="Sub">CR</span>) ≥30 mL/min was comparable to that observed in healthy subjects with normal renal function. However, there was a trend toward decreasing serum protein binding among subjects with CL<span class="Sub">CR</span> &lt;30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%). The protein binding of daptomycin in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B) was similar to that in healthy adult subjects.</p>
<p>The volume of distribution at steady-state (V<span class="Sub">ss</span>) of daptomycin in healthy adult subjects was approximately 0.1 L/kg and was independent of dose.</p>
<p><span class="Emphasis"><span class="Bold">Metabolism</span></span></p>
<p>In <span class="Italics">in vitro</span> studies, daptomycin was not metabolized by human liver microsomes.</p>
<p>In 5 healthy adults after infusion of radiolabeled <span class="Sup">14</span>C-daptomycin, the plasma total radioactivity was similar to the concentration determined by microbiological assay. Inactive metabolites were detected in urine, as determined by the difference between total radioactive concentrations and microbiologically active concentrations. In a separate study, no metabolites were observed in plasma on Day 1 following the administration of Daptomycin for Injection at 6 mg/kg to subjects. Minor amounts of three oxidative metabolites and one unidentified compound were detected in urine. The site of metabolism has not been identified.</p>
<p><span class="Emphasis"><span class="Bold">Excretion</span></span></p>
<p>Daptomycin is excreted primarily by the kidneys. In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations), and 5.7% of the administered dose was recovered from feces (collected for up to 9 days) based on total radioactivity.</p>
<p><span class="Emphasis"><span class="Bold">Specific Populations</span></span></p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>Population-derived pharmacokinetic parameters were determined for infected patients (complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [cSSSI] and <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>) and noninfected subjects with various degrees of renal function (<a href="#_Ref419468264">Table 8</a>). Total plasma clearance (CL<span class="Sub">T</span>), elimination half-life (t<span class="Sub">1/2</span>), and volume of distribution at steady-state (V<span class="Sub">ss</span>) in patients with cSSSI were similar to those in patients with <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>. Following administration of Daptomycin for Injection 4 mg/kg q24h, by IV infusion over a 30-minute period, the mean CL<span class="Sub">T</span> was 9%, 22%, and 46% lower among subjects and patients with mild (CL<span class="Sub">CR</span> 50–80 mL/min), moderate (CL<span class="Sub">CR</span> 30–&lt;50 mL/min), and severe (CL<span class="Sub">CR</span> &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively, than in those with normal renal function (CL<span class="Sub">CR</span> &gt;80 mL/min). The mean steady-state systemic exposure (AUC), t<span class="Sub">1/2</span>, and V<span class="Sub">ss</span> increased with decreasing renal function, although the mean AUC for patients with CL<span class="Sub">CR</span> 30–80 mL/min was not markedly different from the mean AUC for patients with normal renal function. The mean AUC for patients with CL<span class="Sub">CR</span> &lt;30 mL/min and for patients on dialysis (CAPD and hemodialysis dosed post-dialysis) was approximately 2 and 3 times higher, respectively, than for patients with normal renal function. The mean C<span class="Sub">max</span> ranged from 60 to 70 mcg/mL in patients with CL<span class="Sub">CR</span> ≥30 mL/min, while the mean C<span class="Sub">max</span> for patients with CL<span class="Sub">CR</span> &lt;30 mL/min ranged from 41 to 58 mcg/mL. After administration of Daptomycin for Injection 6 mg/kg q24h, by IV infusion over a 30-minute period the mean C<span class="Sub">max</span> ranged from 80 to 114 mcg/mL in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and was similar to that of patients with normal renal function.</p>
<a name="_Ref419468264"></a><table width="100%">
<caption><span>Table 8. Mean (SD) Daptomycin Population Pharmacokinetic Parameters Following Infusion of Daptomycin for Injection 4 mg/kg or 6 mg/kg to Infected Patients and Noninfected Subjects with Various Degrees of Renal Function</span></caption>
<col width="26%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="12%">
<col width="12%">
<col width="10%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="13" valign="top">Note: Daptomycin for Injection was administered over a 30-minute period.</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>CL<span class="Sub">CR</span>, creatinine clearance estimated using the Cockcroft-Gault equation with actual body weight; CAPD, continuous ambulatory peritoneal dialysis; AUC<span class="Sub">0-∞</span>, area under the concentration-time curve extrapolated to infinity; AUC<span class="Sub">ss</span>, area under the concentration-time curve calculated over the 24-hour dosing interval at steady-state; C<span class="Sub">min,ss</span>, trough concentration at steady-state; NA, not applicable.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Parameters obtained following a single dose from patients with complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and healthy subjects.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>Parameters obtained at steady-state from patients with <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Renal Function</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="6" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Pharmacokinetic Parameters</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">t<span class="Sub">1/2</span></span><a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a></span></p>
<p><span class="Emphasis"><span class="Bold">(h)</span></span><br><span class="Emphasis"><span class="Bold">4 mg/kg</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">V<span class="Sub">ss</span></span><a href="#footnote-12" class="Sup">†</a></span></p>
<p><span class="Emphasis"><span class="Bold">(L/kg)</span></span><br><span class="Emphasis"><span class="Bold">4 mg/kg</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">CL<span class="Sub">T</span></span><a href="#footnote-12" class="Sup">†</a></span></p>
<p><span class="Emphasis"><span class="Bold">(mL/h/kg)</span></span><br><span class="Emphasis"><span class="Bold">4 mg/kg</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">AUC<span class="Sub">0-∞</span></span><a href="#footnote-12" class="Sup">†</a></span></p>
<p><span class="Emphasis"><span class="Bold">(mcg•h/mL)</span></span><br><span class="Emphasis"><span class="Bold">4 mg/kg</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">AUC<span class="Sub">ss</span></span><a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a></span></p>
<p><span class="Emphasis"><span class="Bold">(mcg•h/mL)</span></span><br><span class="Emphasis"><span class="Bold">6 mg/kg</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">C<span class="Sub">min</span></span><span class="Sub">,ss</span><a href="#footnote-13" class="Sup">‡</a></span></p>
<p><span class="Emphasis"><span class="Bold">(mcg/mL)</span></span><br><span class="Emphasis"><span class="Bold">6 mg/kg</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Normal</p>
<p>(CL<span class="Sub">CR</span> &gt;80 mL/min)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">9.39 (4.74)</p>
<p>N=165</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">0.13 (0.05)</p>
<p>N=165</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">10.9 (4.0)</p>
<p>N=165</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">417 (155)</p>
<p>N=165</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">545 (296)</p>
<p>N=62</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">6.9 (3.5)</p>
<p>N=61</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p>
<p>(CL<span class="Sub">CR</span> 50–80 mL/min)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">10.75 (8.36)</p>
<p>N=64</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">0.12 (0.05)</p>
<p>N=64</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">9.9 (4.0)</p>
<p>N=64</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">466 (177)</p>
<p>N=64</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">637 (215)</p>
<p>N=29</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">12.4 (5.6)</p>
<p>N=29</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p>
<p>(CL<span class="Sub">CR</span> 30–&lt;50 mL/min)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">14.70 (10.50)</p>
<p>N=24</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">0.15 (0.06)</p>
<p>N=24</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">8.5 (3.4)</p>
<p>N=24</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">560 (258)</p>
<p>N=24</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">868 (349)</p>
<p>N=15</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">19.0 (9.0)</p>
<p>N=14</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p>
<p>(CL<span class="Sub">CR</span> &lt;30 mL/min)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">27.83 (14.85)</p>
<p>N=8</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">0.20 (0.15)</p>
<p>N=8</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">5.9 (3.9)</p>
<p>N=8</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">925 (467)</p>
<p>N=8</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1050, 892</p>
<p>N=2</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">24.4, 21.4</p>
<p>N=2</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Hemodialysis </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">30.51 (6.51)</p>
<p>N=16</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">0.16 (0.04)</p>
<p>N=16</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">3.9 (2.1)</p>
<p>N=16</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1193 (399)</p>
<p>N=16</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">NA</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">CAPD </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">27.56 (4.53)</p>
<p>N=5</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">0.11 (0.02)</p>
<p>N=5</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">2.9 (0.4)</p>
<p>N=5</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1409 (238)</p>
<p>N=5</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">NA</p></td>
</tr>
</tbody>
</table>
<p>Because renal excretion is the primary route of elimination, adjustment of Daptomycin for Injection dosage interval is necessary in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> &lt;30 mL/min) [<span class="Italics">see</span><span class="Emphasis"> </span><span class="Italics"><a href="#c473a928-a0be-4fdf-bfc8-138991d50649">Dosage and Administration (2.4)</a></span>].</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>The pharmacokinetics of daptomycin were evaluated in 10 subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B) and compared with those in healthy volunteers (N=9) matched for gender, age, and weight. The pharmacokinetics of daptomycin were not altered in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. No dosage adjustment is warranted when Daptomycin for Injection is administered to patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The pharmacokinetics of daptomycin in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) have not been evaluated.</p>
<p><span class="Emphasis"><span class="Bold">Gender</span></span></p>
<p>No clinically significant gender-related differences in daptomycin pharmacokinetics have been observed. No dosage adjustment is warranted based on gender when Daptomycin for Injection is administered.</p>
<p><span class="Emphasis"><span class="Bold">Geriatric</span></span></p>
<p>The pharmacokinetics of daptomycin were evaluated in 12 healthy elderly subjects (≥75 years of age) and 11 healthy young controls (18 to 30 years of age). Following administration of a single 4 mg/kg dose of Daptomycin for Injection by IV infusion over a 30-minute period, the mean total clearance of daptomycin was approximately 35% lower and the mean AUC<span class="Sub">0-∞</span> was approximately 58% higher in elderly subjects than in healthy young subjects. There were no differences in C<span class="Sub">max</span> [<span class="Italics">see</span> <span class="Italics"><a href="#a95cb527-871d-4be4-a666-b2828517e026">Use in Specific Populations (8.5)</a></span>].</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></span></span></p>
<p>The pharmacokinetics of daptomycin were evaluated in 6 moderately obese (Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index [BMI] 25 to 39.9 kg/m<span class="Sup">2</span>) and 6 extremely obese (BMI ≥40 kg/m<span class="Sup">2</span>) subjects and controls matched for age, gender, and renal function. Following administration of Daptomycin for Injection by IV infusion over a 30-minute period as a single 4 mg/kg IV dose based on total body weight, the total plasma clearance of daptomycin normalized to total body weight was approximately 15% lower in moderately obese subjects and 23% lower in extremely obese subjects than in nonobese controls. The AUC<span class="Sub">0-∞</span> of daptomycin was approximately 30% higher in moderately obese subjects and 31% higher in extremely obese subjects than in nonobese controls. The differences were most likely due to differences in the renal clearance of daptomycin. No adjustment of Daptomycin for Injection dosage is warranted in obese patients.</p>
<p><span class="Emphasis"><span class="Bold">Pediatric</span></span></p>
<p>The pharmacokinetics of daptomycin in pediatric populations (&lt;18 years of age) have not been established [<span class="Italics">see</span> <span class="Italics"><a href="#da55a8b1-24bc-4507-b2d6-120464381270">Nonclinical Toxicology (13.2)</a></span>].</p>
<p><span class="Emphasis"><span class="Bold">Drug-Drug Interactions</span></span></p>
<p><span class="Bold"><span class="Italics">In Vitro</span> Studies</span></p>
<p><span class="Italics">In vitro</span> studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4. It is unlikely that daptomycin will inhibit or induce the metabolism of drugs metabolized by the P450 system.</p>
<p><span class="Emphasis"><span class="Bold">Aztreonam</span></span></p>
<p>In a study in which 15 healthy adult subjects received a single dose of Daptomycin for Injection 6 mg/kg IV and a combination dose of Daptomycin for Injection 6 mg/kg IV and aztreonam 1 g IV, administered over a 30-minute period, the C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span> of daptomycin were not significantly altered by aztreonam.</p>
<p><span class="Emphasis"><span class="Bold">Tobramycin</span></span></p>
<p>In a study in which 6 healthy adult males received a single dose of Daptomycin for Injection 2 mg/kg IV, tobramycin 1 mg/kg IV, and both in combination, administered over a 30-minute period, the mean C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span> of daptomycin were 12.7% and 8.7% higher, respectively, when Daptomycin for Injection was coadministered with tobramycin. The mean C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span> of tobramycin were 10.7% and 6.6% lower, respectively, when tobramycin was coadministered with Daptomycin for Injection. These differences were not statistically significant. The interaction between daptomycin and tobramycin with a clinical dose of Daptomycin for Injection is unknown.</p>
<p><span class="Emphasis"><span class="Bold">Warfarin</span></span></p>
<p>In 16 healthy subjects, administration of Daptomycin for Injection 6 mg/kg q24h by IV infusion over a 30-minute period for 5 days, with coadministration of a single oral dose of warfarin (25 mg) on the 5th day, had no significant effect on the pharmacokinetics of either drug and did not significantly alter the INR (International Normalized Ratio).</p>
<p><span class="Emphasis"><span class="Bold">Simvastatin</span></span></p>
<p>In 20 healthy subjects on a stable daily dose of simvastatin 40 mg, administration of Daptomycin for Injection 4 mg/kg q24h by IV infusion over a 30-minute period for 14 days (N=10) had no effect on plasma trough concentrations of simvastatin and was not associated with a higher incidence of adverse events, including skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, than in subjects receiving placebo once daily (N=10) [<span class="Italics">see</span> <span class="Italics"><a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">Warnings and Precautions (5.2)</a></span> <span class="Italics">and</span> <span class="Italics"><a href="#b2f3d3a1-4a3b-413f-a83d-0ec28c48e410">Drug Interactions (7.1)</a></span>].</p>
<p><span class="Emphasis"><span class="Bold">Probenecid</span></span></p>
<p>Concomitant administration of probenecid (500 mg 4 times daily) and a single dose of Daptomycin for Injection 4 mg/kg by IV infusion over a 30-minute period did not significantly alter the C<span class="Sub">max</span> or AUC<span class="Sub">0-∞</span> of daptomycin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="bf76f40d-2184-461c-bf01-77aadbbd3897"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Daptomycin belongs to the cyclic lipopeptide class of antibacterials. Daptomycin has clinical utility in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by aerobic, Gram-positive bacteria. The <span class="Italics">in vitro</span> spectrum of activity of daptomycin encompasses most clinically relevant Gram-positive pathogenic bacteria.</p>
<p>Daptomycin exhibits rapid, concentration-dependent bactericidal activity against Gram-positive bacteria <span class="Italics">in vitro</span>. This has been demonstrated both by time-kill curves and by MBC/MIC (minimum bactericidal concentration/<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>) ratios using broth dilution methodology. Daptomycin maintained bactericidal activity <span class="Italics">in vitro</span> against stationary phase <span class="Italics">S. aureus</span> in simulated endocardial vegetations. The clinical significance of this is not known.</p>
<p><span class="Emphasis"><span class="Bold">Mechanism of Action</span></span></p>
<p>The mechanism of action of daptomycin is distinct from that of any other antibacterial. Daptomycin binds to bacterial cell membranes and causes a rapid depolarization of membrane potential. This loss of membrane potential causes inhibition of DNA, RNA, and protein synthesis, which results in bacterial <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.</p>
<p><span class="Emphasis"><span class="Bold">Mechanism of Resistance</span></span></p>
<p>The mechanism(s) of daptomycin resistance is not fully understood. Currently, there are no known transferable elements that confer resistance to daptomycin.</p>
<p><span class="Emphasis"><span class="Bold">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> (cSSSI) Trials</span></span></p>
<p>The emergence of daptomycin non-susceptible isolates occurred in 2 infected patients across the set of Phase 2 and pivotal Phase 3 clinical trials of cSSSI. In one case, a non-susceptible <span class="Italics">S. aureus</span> was isolated from a patient in a Phase 2 trial who received Daptomycin for Injection at less than the protocol-specified dose for the initial 5 days of therapy. In the second case, a non-susceptible <span class="Italics">Enterococcus faecalis</span> was isolated from a patient with an infected chronic <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus ulcer</span> who was enrolled in a salvage trial.</p>
<p><span class="Bold"><span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> and Other Post-Approval Trials</span></p>
<p>In subsequent clinical trials, non-susceptible isolates were recovered. <span class="Italics">S. aureus</span> was isolated from a patient in a compassionate-use trial and from 7 patients in the <span class="Italics">S.</span><span class="Italics"> aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> trial [<span class="Italics">see</span><span class="Emphasis"> </span><span class="Italics"><a href="#be967a28-5b0d-4f82-b7c2-1c36c2c748b5">Clinical Studies (14.2)</a></span>]. An <span class="Italics">E.</span><span class="Italics"> faecium</span> was isolated from a patient in a vancomycin-resistant enterococci trial.</p>
<p><span class="Emphasis"><span class="Bold">Interactions with Other Antibacterials</span></span></p>
<p><span class="Italics">In vitro</span> studies have investigated daptomycin interactions with other antibacterials. Antagonism, as determined by kill curve studies, has not been observed. <span class="Italics">In vitro</span> synergistic interactions of daptomycin with aminoglycosides, β-lactam antibacterials, and rifampin have been shown against some isolates of staphylococci (including some methicillin-resistant isolates) and enterococci (including some vancomycin-resistant isolates).</p>
<p><span class="Bold">Activity <span class="Italics">In Vitro</span> and <span class="Italics">In Vivo</span></span></p>
<p>Daptomycin has been shown to be active against most isolates of the following Gram-positive bacteria <span class="Underline">both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span>, as described in <span class="Italics"><a href="#f12c0ba4-d452-49a6-b33f-280110f32fd1">Indications and Usage (1)</a></span>.</p>
<p><span class="Emphasis"><span class="Bold">Gram-Positive Bacteria</span></span></p>
<p><span class="Italics">Enterococcus faecalis</span> (vancomycin-susceptible isolates only)<br><span class="Italics">Staphylococcus aureus</span> (including methicillin-resistant isolates)<br><span class="Italics">Streptococcus agalactiae</span><br><span class="Italics">Streptococcus dysgalactiae</span> subsp. <span class="Italics">equisimilis</span><br><span class="Italics">Streptococcus pyogenes</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Underline">but their clinical significance is unknown</span>. At least 90% of the following Gram-positive bacteria exhibit an <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for daptomycin versus the bacterial genus (<a href="#_Ref419445544">Table 9</a>). However, the efficacy of Daptomycin for Injection in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria has not been established in adequate and well-controlled clinical trials.</p>
<p><span class="Bold">Gram-Positive Bacteria</span></p>
<p><span class="Italics">Corynebacterium jeikeium</span><br><span class="Italics">Enterococcus faecalis</span> (vancomycin-resistant isolates)<br><span class="Italics">Enterococcus faecium</span> (including vancomycin-resistant isolates)<br><span class="Italics">Staphylococcus epidermidis</span> (including methicillin-resistant isolates)<br><span class="Italics">Staphylococcus haemolyticus</span></p>
<p><span class="Emphasis"><span class="Bold">Susceptibility Testing Methods</span></span></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility tests for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<p><span class="Emphasis"><span class="Bold">Dilution Techniques</span></span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized broth test method<span class="Sup">2,3 </span>with the broth adjusted to a calcium content of 50 mg/L. The use of the agar dilution method is not recommended with daptomycin<span class="Sup">3</span>. The MICs should be interpreted according to the criteria listed in <a href="#_Ref419445544">Table 9</a>.</p>
<a name="_Ref419445544"></a><table width="100%">
<caption><span>Table 9. Susceptibility Interpretive Criteria for Daptomycin</span></caption>
<col width="51%">
<col width="16%">
<col width="18%">
<col width="16%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">Note: S, Susceptible; I, Intermediate; R, Resistant.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>The MIC interpretive criteria for <span class="Italics">S. aureus</span> and <span class="Italics">E. faecalis</span> are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L; the MIC interpretive criteria for <span class="Italics">Streptococcus</span> spp. other than <span class="Italics">S. pneumoniae</span> are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L, supplemented with 2 to 5% lysed horse blood, inoculated with a direct colony suspension and incubated in ambient air at 35°C for 20 to 24 hours.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>The current absence of data on daptomycin-resistant isolates precludes defining any categories other than “Susceptible.? Isolates yielding test results suggestive of a “Non-Susceptible? category should be retested, and if the result is confirmed, the isolate should be submitted to a reference laboratory for further testing.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Pathogen</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Broth Dilution MIC</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a></span><br><span class="Emphasis"><span class="Bold">(mcg/mL)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">S</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">I</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">R</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">Staphylococcus aureus</span><br>(methicillin-susceptible and methicillin-resistant)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">≤1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">(<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">(<a href="#footnote-15" class="Sup">†</a>)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus agalactiae</span>, and <span class="Italics">Streptococcus dysgalactiae</span> subsp. <span class="Italics">equisimilis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">≤1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">(<a href="#footnote-15" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">(<a href="#footnote-15" class="Sup">†</a>)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">Enterococcus faecalis</span><br>(vancomycin-susceptible only)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">≤4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">(<a href="#footnote-15" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">(<a href="#footnote-15" class="Sup">†</a>)</p></td>
</tr>
</tbody>
</table>
<p>A report of “Susceptible? indicates that the antimicrobial is likely to inhibit the growth of the pathogen if the antimicrobial compound reaches the concentration at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen.</p>
<p><span class="Emphasis"><span class="Bold">Diffusion Technique</span></span></p>
<p>Quantitative methods that require measurement of zone diameters have not been shown to provide reproducible estimates of the susceptibility of bacteria to daptomycin. The use of the disk diffusion method is not recommended with daptomycin<span class="Sup">3,4</span>.</p>
<p><span class="Emphasis"><span class="Bold">Quality Control</span></span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test<span class="Sup">2,3</span>. Standard daptomycin powder should provide the range of MIC values noted in <a href="#_Ref419465876">Table 10</a>. </p>
<a name="_Ref419465876"></a><table width="100%">
<caption><span>Table 10. Acceptable Quality Control Ranges for Daptomycin to Be Used in Validation of Susceptibility Test Results</span></caption>
<col width="50%">
<col width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>The quality control ranges for <span class="Italics">S. aureus</span> and <span class="Italics">E. faecalis</span> are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L; the quality control range for <span class="Italics">Streptococcus pneumoniae</span> is applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L, supplemented with 2 to 5% lysed horse blood, inoculated with a direct colony suspension and incubated in ambient air at 35°C for 20 to 24 hours.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>This <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> may be used for validation of susceptibility test results when testing <span class="Italics">Streptococcus</span> spp. other than <span class="Italics">S. pneumoniae</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Quality Control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Broth Dilution MIC Range</span><a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a></span><br><span class="Emphasis"><span class="Bold">(mcg/mL)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics">Enterococcus faecalis</span> ATCC 29212</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1–4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics">Staphylococcus aureus</span> ATCC 29213</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.12–1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics">Streptococcus pneumoniae</span> ATCC 49619<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.06–0.5</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="a63491d7-d904-493b-a040-c1cf7aaf08df"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="bdb7806c-c66b-4673-90bd-92e5d48467c9"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in animals have not been conducted to evaluate the carcinogenic potential of Daptomycin for Injection. However, neither mutagenic nor clastogenic potential was found in a battery of genotoxicity tests, including the Ames assay, a mammalian cell gene mutation assay, a test for chromosomal aberrations in Chinese hamster ovary cells, an <span class="Italics">in vivo</span> micronucleus assay, an <span class="Italics">in vitro</span> DNA repair assay, and an <span class="Italics">in vivo</span> sister chromatid exchange assay in Chinese hamsters.</p>
<p>Daptomycin did not affect the fertility or reproductive performance of male and female rats when administered intravenously at doses up to 150 mg/kg/day, which is approximately 9 times the estimated human exposure level based upon AUCs.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="da55a8b1-24bc-4507-b2d6-120464381270"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Emphasis"><span class="Bold">Adult Animals</span></span></p>
<p>In animals, daptomycin administration has been associated with effects on skeletal muscle. However, there were no changes in cardiac or smooth muscle. Skeletal muscle effects were characterized by microscopic degenerative/regenerative changes and variable elevations in creatine phosphokinase (CPK). No <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> was evident in repeat-dose studies up to the highest doses tested in rats (150 mg/kg/day) and dogs (100 mg/kg/day). The degree of skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> showed no increase when treatment was extended from 1 month to up to 6 months. Severity was dose-dependent. All muscle effects, including microscopic changes, were fully reversible within 30 days following the cessation of dosing.</p>
<p>In adult animals, effects on peripheral nerve (characterized by axonal degeneration and frequently accompanied by significant losses of patellar reflex, gag reflex, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> perception) were observed at daptomycin doses higher than those associated with skeletal <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. Deficits in the dogs’ patellar reflexes were seen within 2 weeks after the start of treatment at 40 mg/kg/day (9 times the human C<span class="Sub">max</span> at the 6 mg/kg/day dose), with some clinical improvement noted within 2 weeks after the cessation of dosing. However, at 75 mg/kg/day for 1 month, 7 of 8 dogs failed to regain full patellar reflex responses within a 3-month recovery period. In a separate study in dogs receiving doses of 75 and 100 mg/kg/day for 2 weeks, minimal residual histological changes were noted at 6 months after the cessation of dosing. However, recovery of peripheral nerve function was evident.</p>
<p>Tissue distribution studies in rats showed that daptomycin is retained in the kidney but appears to penetrate the blood-brain barrier only minimally following single and multiple doses.</p>
<p><span class="Emphasis"><span class="Bold">Juvenile Animals </span></span></p>
<p>Target organs of daptomycin-related effects in 7-week-old juvenile dogs were skeletal muscle and nerve, the same target organs as in adult dogs. In juvenile dogs, nerve effects were noted at lower daptomycin blood concentrations than in adult dogs following 28 days of dosing. In contrast to adult dogs, juvenile dogs also showed evidence of effects in nerves of the spinal cord as well as peripheral nerves after 28 days of dosing. No nerve effects were noted in juvenile dogs following 14 days of dosing at doses up to 75 mg/kg/day. </p>
<p>Administration of daptomycin to 7-week-old juvenile dogs for 28 days at doses of 50 mg/kg/day produced minimal degenerative effects on the peripheral nerve and spinal cord in several animals, with no corresponding clinical signs. A dose of 150 mg/kg/day for 28 days produced minimal degeneration in the peripheral nerve and spinal cord as well as minimal to mild degeneration of the skeletal muscle in a majority of animals, accompanied by slight to severe <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> evident in most dogs. Following a 28-day recovery phase, microscopic examination revealed recovery of the skeletal muscle and the ulnar nerve effects, but nerve degeneration in the sciatic nerve and spinal cord was still observed in all 150 mg/kg/day dogs. </p>
<p>Following once-daily administration of daptomycin to juvenile dogs for 28 days, microscopic effects in nerve tissue were noted at a C<span class="Sub">max</span> value of 417 mcg/mL, which is approximately 3-fold less than the C<span class="Sub">max</span> value associated with nerve effects in adult dogs treated once daily with daptomycin for 28 days (1308 mcg/mL).</p>
<p><span class="Bold">Neonatal Animals</span></p>
<p>Neonatal dogs (4 to 31 days old) were more sensitive to daptomycin-related adverse nervous system and/or muscular system effects than either juvenile or adult dogs. In neonatal dogs, adverse nervous system and/or muscular system effects were associated with a C<span class="Sub">max</span> value approximately 3-fold less than the C<span class="Sub">max</span> in juvenile dogs, and 9-fold less than the C<span class="Sub">max</span> in adult dogs following 28 days of dosing. At a dose of 25 mg/kg/day with associated C<span class="Sub">max</span> and AUC<span class="Sub">inf</span> values of 147 mcg/mL and 717 mcg•h/mL, respectively (1.6 and 1.0-fold the adult human C<span class="Sub">max</span> and AUC, respectively, at the 6 mg/kg/day dose), mild clinical signs of <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span> and one incidence of <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> were observed with no corresponding effect on body weight. These effects were found to be reversible within 28 days after treatment had stopped. </p>
<p>At higher dose levels of 50 and 75 mg/kg/day with associated C<span class="Sub">max</span> and AUC<span class="Sub">inf</span> values of ≥321 mcg/mL and ≥1470 mcg•h/mL, respectively, marked clinical signs of <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> in the limbs, and impaired use of limbs were observed. Resulting decreases in body weights and overall body condition at doses ≥50 mg/kg/day necessitated early discontinuation by PND19. </p>
<p>Histopathological assessment did not reveal any daptomycin-related changes in the peripheral and central nervous system tissue, as well as in the skeletal muscle or other tissues assessed, at any dose level. </p>
<p>No adverse effects were observed in the dogs that received daptomycin at 10 mg/kg/day, the NOAEL, with associated C<span class="Sub">max</span> and AUC<span class="Sub">inf</span> values of 62 mcg/mL and 247 mcg•h/mL, respectively (or 0.6 and 0.4‑fold the adult human C<span class="Sub">max</span> and AUC, respectively at the 6 mg/kg dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ea53f7c6-a2d4-4902-a904-337d3ce68837"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="a86eac71-a11b-4ff0-8582-04e7c5063861"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Adult patients with clinically documented complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI) (<a href="#_Ref419446640">Table 11</a>) were enrolled in two randomized, multinational, multicenter, investigator-blinded trials comparing Daptomycin for Injection (4 mg/kg IV q24h) with either vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g IV per day). Patients could switch to oral therapy after a minimum of 4 days of IV treatment if clinical improvement was demonstrated. Patients known to have <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> at baseline were excluded. Patients with creatinine clearance (CL<span class="Sub">CR</span>) between 30 and 70 mL/min were to receive a lower dose of Daptomycin for Injection as specified in the protocol; however, the majority of patients in this subpopulation did not have the dose of Daptomycin for Injection adjusted. </p>
<a name="_Ref419446640"></a><table width="100%">
<caption><span>Table 11. Investigator’s Primary Diagnosis in the cSSSI Trials (Population: Intent-to-Treat)</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="26%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>The majority of cases were subsequently categorized as complicated <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, major <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, or traumatic <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infections</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Primary Diagnosis</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Emphasis"><span class="Bold">Patients</span></span><br><span class="Bold"><span class="Emphasis">(Daptomycin for Injection / Comparator</span><a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a><span class="Emphasis">)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">Study 9801</span></span></p>
<p><span class="Emphasis"><span class="Bold">N=264 / N=266</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">Study 9901</span></span></p>
<p><span class="Emphasis"><span class="Bold">N=270 / N=292</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Emphasis"><span class="Bold">Pooled</span></span></p>
<p><span class="Emphasis"><span class="Bold">N=534 / N=558</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">Wound Infection</span> </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">99 (38%) / 116 (44%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">102 (38%) / 108 (37%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">201 (38%) / 224 (40%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">Major <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">55 (21%) / 43 (16%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">59 (22%) / 65 (22%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">114 (21%) / 108 (19%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">71 (27%) / 75 (28%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">53 (20%) / 68 (23%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">124 (23%) / 143 (26%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">Other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">39 (15%) / 32 (12%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">56 (21%) / 51 (18%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">95 (18%) / 83 (15%)</p></td>
</tr>
</tbody>
</table>
<p>One trial was conducted primarily in the United States and South Africa (study 9801), and the second was conducted at non-US sites only (study 9901). The two trials were similar in design but differed in patient characteristics, including history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. There were a total of 534 patients treated with Daptomycin for Injection and 558 treated with comparator in the two trials. The majority (89.7%) of patients received IV medication exclusively.</p>
<p>The efficacy endpoints in both trials were the clinical success rates in the intent-to-treat (ITT) population and in the clinically evaluable (CE) population. In study 9801, clinical success rates in the ITT population were 62.5% (165/264) in patients treated with Daptomycin for Injection and 60.9% (162/266) in patients treated with comparator drugs. Clinical success rates in the CE population were 76.0% (158/208) in patients treated with Daptomycin for Injection and 76.7% (158/206) in patients treated with comparator drugs. In study 9901, clinical success rates in the ITT population were 80.4% (217/270) in patients treated with Daptomycin for Injection and 80.5% (235/292) in patients treated with comparator drugs. Clinical success rates in the CE population were 89.9% (214/238) in patients treated with Daptomycin for Injection and 90.4% (226/250) in patients treated with comparator drugs.</p>
<p>The success rates by pathogen for microbiologically evaluable patients are presented in <a href="#_Ref419446719">Table 12</a>.</p>
<a name="_Ref419446719"></a><table width="96.56%">
<caption><span>Table 12. Clinical Success Rates by Infecting Pathogen in the cSSSI Trials (Population: Microbiologically Evaluable)</span></caption>
<col width="56%">
<col width="22%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>As determined by the central laboratory.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Pathogen</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Success Rate</span></span><br><span class="Emphasis"><span class="Bold">n/N (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Daptomycin for Injection</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Comparator</span><a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">Methicillin-susceptible <span class="Italics">Staphylococcus aureus</span> (MSSA)<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">170/198 (86%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">180/207 (87%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">Methicillin-resistant <span class="Italics">Staphylococcus aureus</span> (MRSA)<a href="#footnote-21" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">21/28 (75%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25/36 (69%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Italics">Streptococcus pyogenes</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">79/84 (94%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">80/88 (91%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Italics">Streptococcus agalactiae</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">23/27 (85%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22/29 (76%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Italics">Streptococcus dysgalactiae</span> subsp. <span class="Italics">equisimilis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8/8 (100%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9/11 (82%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Italics">Enterococcus faecalis</span> (vancomycin-susceptible only)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">27/37 (73%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">40/53 (76%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="be967a28-5b0d-4f82-b7c2-1c36c2c748b5"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></h2>
<p class="First">The efficacy of Daptomycin for Injection in the treatment of patients with <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> was demonstrated in a randomized, controlled, multinational, multicenter, open-label trial. In this trial, adult patients with at least one positive blood culture for <span class="Italics">S. aureus</span> obtained within 2 calendar days prior to the first dose of study drug and irrespective of source were enrolled and randomized to either Daptomycin for Injection (6 mg/kg IV q24h) or standard of care [an anti-staphylococcal semi-synthetic penicillin 2 g IV q4h (nafcillin, oxacillin, cloxacillin, or flucloxacillin) or vancomycin 1 g IV q12h, each with initial gentamicin 1 mg/kg IV every 8 hours for first 4 days]. Of the patients in the comparator group, 93% received initial gentamicin for a median of 4 days, compared with 1 patient (&lt;1%) in the Daptomycin for Injection group. Patients with prosthetic heart valves, intravascular foreign material that was not planned for removal within 4 days after the first dose of study medication, severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, known <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>, polymicrobial bloodstream <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, creatinine clearance &lt;30 mL/min, and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were excluded.</p>
<p>Upon entry, patients were classified for likelihood of <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> using the modified Duke criteria (Possible, Definite, or Not <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>). Echocardiography, including a transesophageal echocardiogram (TEE), was performed within 5 days following study enrollment. The choice of comparator agent was based on the oxacillin susceptibility of the <span class="Italics">S. aureus</span> isolate. The duration of study treatment was based on the investigator’s clinical diagnosis. Final diagnoses and outcome assessments at Test of Cure (6 weeks after the last treatment dose) were made by a treatment-blinded Adjudication Committee, using protocol-specified clinical definitions and a composite primary efficacy endpoint (clinical and microbiological success) at the Test of Cure visit.</p>
<p>A total of 246 patients ≥18 years of age (124 Daptomycin for Injection, 122 comparator) with <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> were randomized from 48 centers in the US and Europe. In the ITT population, 120 patients received Daptomycin for Injection and 115 received comparator (62 received an anti-staphylococcal semi-synthetic penicillin and 53 received vancomycin). Thirty-five patients treated with an anti-staphylococcal semi-synthetic penicillin received vancomycin initially for 1 to 3 days, pending final susceptibility results for the <span class="Italics">S. aureus</span> isolates. The median age among the 235 patients in the ITT population was 53 years (range: 21 to 91 years); 30/120 (25%) in the Daptomycin for Injection group and 37/115 (32%) in the comparator group were ≥65 years of age. Of the 235 ITT patients, there were 141 (60%) males and 156 (66%) Caucasians across the two treatment groups. In addition, 176 (75%) of the ITT population had <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">systemic inflammatory response syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) at baseline and 85 (36%) had surgical procedures within 30 days prior to onset of the <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>. Eighty-nine patients (38%) had <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> caused by methicillin-resistant <span class="Italics">S. aureus</span> (MRSA). Entry diagnosis was based on the modified Duke criteria and comprised 37 (16%) Definite, 144 (61%) Possible, and 54 (23%) Not <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>. Of the 37 patients with an entry diagnosis of Definite <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, all (100%) had a final diagnosis of infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, and of the 144 patients with an entry diagnosis of Possible <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, 15 (10%) had a final diagnosis of infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> as assessed by the Adjudication Committee. Of the 54 patients with an entry diagnosis of Not <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, 1 (2%) had a final diagnosis of infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> as assessed by the Adjudication Committee.</p>
<p>In the ITT population, there were 182 patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> and 53 patients with infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> as assessed by the Adjudication Committee, including 35 with right-sided <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> and 18 with left-sided <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>. The 182 patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> comprised 121 with complicated <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> and 61 with uncomplicated <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.</p>
<p>Complicated <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> was defined as <span class="Italics">S. aureus</span> isolated from blood cultures obtained on at least 2 different calendar days, and/or metastatic foci of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (deep tissue involvement), and classification of the patient as not having <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> according to the modified Duke criteria. Uncomplicated <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> was defined as <span class="Italics">S. aureus</span> isolated from blood culture(s) obtained on a single calendar day, no metastatic foci of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, no <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of prosthetic material, and classification of the patient as not having <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> according to the modified Duke criteria. The definition of right-sided infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> (RIE) used in the clinical trial was Definite or Possible <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> according to the modified Duke criteria and no echocardiographic evidence of predisposing pathology or active involvement of either the mitral or aortic valve. Complicated RIE comprised patients who were not intravenous drug users, had a positive blood culture for MRSA, serum creatinine ≥2.5 mg/dL, or evidence of extrapulmonary sites of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients who were intravenous drug users, had a positive blood culture for methicillin-susceptible <span class="Italics">S. aureus</span> (MSSA), had serum creatinine &lt;2.5 mg/dL, and were without evidence of extrapulmonary sites of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were considered to have uncomplicated RIE.</p>
<p>The coprimary efficacy endpoints in the trial were the Adjudication Committee success rates at the Test of Cure visit (6 weeks after the last treatment dose) in the ITT and Per Protocol (PP) populations. The overall Adjudication Committee success rates in the ITT population were 44.2% (53/120) in patients treated with Daptomycin for Injection and 41.7% (48/115) in patients treated with comparator (difference = 2.4% [95% CI −10.2, 15.1]). The success rates in the PP population were 54.4% (43/79) in patients treated with Daptomycin for Injection and 53.3% (32/60) in patients treated with comparator (difference = 1.1% [95% CI −15.6, 17.8]).</p>
<p>Adjudication Committee success rates are shown in <a href="#_Ref419446928">Table 13</a>. </p>
<a name="_Ref419446928"></a><table width="100%">
<caption><span>Table 13. Adjudication Committee Success Rates at Test of Cure in the S. aureus <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> Trial (Population: ITT)</span></caption>
<col width="35%">
<col width="20%">
<col width="20%">
<col width="25%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-22" href="#footnote-reference-22">*</a></dt>
<dd>Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV q4h), each with initial low-dose gentamicin.</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">†</a></dt>
<dd>95% Confidence Interval</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">‡</a></dt>
<dd>97.5% Confidence Interval (adjusted for multiplicity)</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">§</a></dt>
<dd>According to the modified Duke criteria<span class="Sup">5</span>
</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">¶</a></dt>
<dd>99% Confidence Interval (adjusted for multiplicity)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Population</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Success Rate</span></span><br><span class="Emphasis"><span class="Bold">n/N (%)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Emphasis"><span class="Bold">Difference:</span></span></p>
<p><span class="Emphasis"><span class="Bold">Daptomycin for Injection − Comparator </span></span></p>
<p><span class="Emphasis"><span class="Bold">(Confidence Interval)</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Emphasis"><span class="Bold">Daptomycin</span></span><br><span class="Emphasis"><span class="Bold">for Injection</span></span><br><span class="Emphasis"><span class="Bold">6 mg/kg</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Comparator</span><a name="footnote-reference-22" href="#footnote-22" class="Sup">*</a></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Overall</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">53/120 (44%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">48/115 (42%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2.4% (−10.2, 15.1)<a name="footnote-reference-23" href="#footnote-23" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold">Baseline Pathogen</span></span></p>
<p>    Methicillin-susceptible <span class="Italics">S. aureus</span></p>
<p>    Methicillin-resistant <span class="Italics">S. aureus</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">33/74 (45%)</p>
<p>20/45 (44%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">34/70 (49%)</p>
<p>14/44 (32%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">−4.0% (−22.6, 14.6)<a name="footnote-reference-24" href="#footnote-24" class="Sup">‡</a></p>
<p>12.6% (−10.2, 35.5)<a href="#footnote-24" class="Sup">‡</a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Entry Diagnosis</span><a name="footnote-reference-25" href="#footnote-25" class="Sup">§</a></span></p>
<p>    Definite or Possible Infective     <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></p>
<p>    Not Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">41/90 (46%)</p>
<p>12/30 (40%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">37/91 (41%)</p>
<p>11/24 (46%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">4.9% (−11.6, 21.4)<a href="#footnote-24" class="Sup">‡</a></p>
<p>−5.8% (−36.2, 24.5)<a href="#footnote-24" class="Sup">‡</a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Emphasis"><span class="Bold">Final Diagnosis</span></span></p>
<p>    Uncomplicated <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></p>
<p>    Complicated <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">18/32 (56%)</p>
<p>26/60 (43%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">16/29 (55%)</p>
<p>23/61 (38%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">1.1% (−31.7, 33.9)<a name="footnote-reference-26" href="#footnote-26" class="Sup">¶</a></p>
<p>5.6% (−17.3, 28.6)<a href="#footnote-26" class="Sup">¶</a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Right-Sided Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">8/19 (42%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">7/16 (44%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">−1.6% (−44.9, 41.6)<a href="#footnote-26" class="Sup">¶</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">        Uncomplicated Right-Sided         Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">3/6 (50%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1/4 (25%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">25.0% (−51.6, 100.0)<a href="#footnote-26" class="Sup">¶</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">        Complicated Right-Sided         Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">5/13 (39%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">6/12 (50%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">−11.5% (−62.4, 39.4)<a href="#footnote-26" class="Sup">¶</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Left-Sided Infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1/9 (11%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2/9 (22%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">−11.1% (−55.9, 33.6)<a href="#footnote-26" class="Sup">¶</a></p></td>
</tr>
</tbody>
</table>
<p>Eighteen (18/120) patients in the Daptomycin for Injection arm and 19/116 patients in the comparator arm died during the trial. These comprise 3/28 Daptomycin for Injection-treated patients and 8/26 comparator-treated patients with <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, as well as 15/92 Daptomycin for Injection-treated patients and 11/90 comparator-treated patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>. Among patients with persisting or relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 8/19 Daptomycin for Injection-treated patients and 7/11 comparator-treated patients died.</p>
<p>Overall, there was no difference in time to clearance of <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> between Daptomycin for Injection and comparator. The median time to clearance in patients with MSSA was 4 days and in patients with MRSA was 8 days.</p>
<p>Failure of treatment due to persisting or relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was assessed by the Adjudication Committee in 19/120 (16%) Daptomycin for Injection-treated patients (12 with MRSA and 7 with MSSA) and 11/115 (10%) comparator-treated patients (9 with MRSA treated with vancomycin and 2 with MSSA treated with an anti-staphylococcal semi-synthetic penicillin). Among all failures, isolates from 6 Daptomycin for Injection-treated patients and 1 vancomycin-treated patient developed increasing MICs (reduced susceptibility) by central laboratory testing during or following therapy. Most patients who failed due to persisting or relapsing <span class="Italics">S. aureus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> had deep-seated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and did not receive necessary <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> [<span class="Italics">see</span> <span class="Italics"><a href="#cc0077c1-7e0a-4a79-9e34-7d3a46d0bf72">Warnings and Precautions (5.7)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="f38fdc4a-3865-4c2d-be4b-613f7b32fd70"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Buitrago MI, Crompton JA, Bertolami S, North DS, Nathan RA. Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant <span class="Italics">Staphylococcus aureus</span> <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>. Pharmacotherapy 2009;29(3):347–351.</dd>
<dt>2.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—ninth edition. CLSI Document M07-A9; Wayne, PA. 2012.</dd>
<dt>3.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI Document M100-S22; Wayne, PA. 2012.</dd>
<dt>4.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard—eleventh edition. CLSI Document M02-A11; Wayne, PA. 2012.</dd>
<dt>5.</dt>
<dd>Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>. Clin Infect Dis 2000;30:633–638.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ad93484b-2811-4284-a97b-799df3170813"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Daptomycin for Injection is supplied as sterile <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light brown lyophilized cake or powder in a single-use 10-mL vial containing 500 mg of daptomycin: Package of 1 (NDC 0409-0106-01)</p>
<p>Store original packages at refrigerated temperatures, 2 to 8°C (36 to 46°F); avoid excessive heat.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="b796a31b-7e8d-469a-918f-0a0c2a76272e"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, could occur and that serious reactions require immediate treatment. Patients should report any previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Daptomycin for Injection [<span class="Italics">see</span> <span class="Italics"><a href="#b17598ba-6b3c-4dc4-8dd0-263a3ca8d502">Warnings and Precautions (5.1)</a></span>].</p>
<p>Patients should be advised to report <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, especially in the forearms and lower legs, as well as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> [<span class="Italics">see <a href="#f92e9a2d-1c00-45aa-998d-e0bd02231d61">Warnings and Precautions</a></span> <span class="Italics">(<a href="#f98a3b2e-65f7-49b0-8af8-63be628e4e15">5.2</a>, <a href="#a4a640d3-1841-4091-b207-fb44c213501f">5.4</a>)</span>].</p>
<p>Patients should be advised to report any symptoms of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">breathlessness</span>, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> [<span class="Italics">see</span> <span class="Italics"><a href="#dc1f3cc1-60ae-4db2-a0cd-cad307deb741">Warnings and Precautions (5.3)</a></span>].</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibacterials that usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), even as late as 2 or more months after having received the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible [<span class="Italics">see</span> <span class="Italics"><a href="#aa7bd111-c3f4-4a9f-9c6d-2d2b5c13ca4a">Warnings and Precautions (5.6)</a></span>].</p>
<p>Patients should be counseled that antibacterial drugs, including Daptomycin for Injection, should be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Daptomycin for Injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be administered exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Daptomycin for Injection or other antibacterial drugs in the future.</p>
<p> </p>
<p> <br>                                                                         EN-3750</p>
<p>Hospira, Inc., Lake Forest, IL 60045 USA                                                                                            <a name="id692805558"></a><img alt="Hospira logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e33053a5-38cd-4a34-8566-208f94f55714&amp;name=hospira-logo.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_537d34b0-f181-4d3d-9daa-1389eba8f3fb"></a><a name="section-17"></a><p></p>
<h1>CA-3378</h1>
<p class="First"><span class="Emphasis"><span class="Bold"></span></span></p>
<div class="Figure">
<a name="id-2036330423"></a><img alt="Carton NDC 0409-0106-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e33053a5-38cd-4a34-8566-208f94f55714&amp;name=daptomycin-for-injection1-figure-2-jCA-3378.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DAPTOMYCIN 		
					</strong><br><span class="contentTableReg">daptomycin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-0106</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DAPTOMYCIN</strong> (DAPTOMYCIN) </td>
<td class="formItem">DAPTOMYCIN</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-0106-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202857</td>
<td class="formItem">09/12/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d86d83cb-30cf-47fa-bb0c-18ce2179677f</div>
<div>Set id: e33053a5-38cd-4a34-8566-208f94f55714</div>
<div>Version: 2</div>
<div>Effective Time: 20150513</div>
</div>
</div> <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
